Form 4: Puma Biotechnology CFO Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold a total of 9,522 shares of common stock over two days in July 2025, pursuant to a Rule 10b5-1 trading plan.
Summary
- Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology, Inc. (PBYI), reported sales of common stock.
- On July 8, 2025, 5,587 shares were sold at a price of $3.533 per share.
- On July 9, 2025, an additional 3,935 shares were sold at a price of $3.535 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2020.
- Following these sales, Maximo F. Nougues beneficially owns 204,229 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral. The filing reports routine insider stock sales under a pre-arranged 10b5-1 plan, which is a common practice and does not inherently indicate positive or negative sentiment about the company's prospects.
Positives
- Transactions were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled sales and reducing concerns about insider trading based on non-public information.
Negatives
- Chief Financial Officer Maximo F. Nougues sold a total of 9,522 shares of common stock.
Risks
- No specific company risks are detailed in this Form 4 filing.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Management Comments
- No direct management comments or notable quotes are provided in this Form 4 filing, beyond the signature confirming the filing.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Comparison to Industry Standards
- Not applicable; this Form 4 reports an individual insider transaction and does not contain data for industry comparison.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | NA | Maximo F. Nougues | NA | Maximo F. Nougues is the current Chief Financial Officer and reporting person; no change is indicated. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- No legal proceedings or regulatory matters are reported in this Form 4 filing.
Related Party Transactions
- No related party transactions are reported in this Form 4 filing beyond the insider's stock sales.
Stakeholder Impact
- The sale of shares by a Chief Financial Officer, even under a 10b5-1 plan, could be perceived by some shareholders as a lack of confidence, though the pre-arranged nature mitigates this. No direct impact on employees, customers, suppliers, or creditors is indicated.
Next Steps
- No specific future actions, events, or milestones are mentioned in this Form 4 filing.
Key Dates
| Date | Description |
|---|---|
| 12-14-2020 | Adoption date of the Rule 10b5-1(c) plan. |
| 07/08/2025 | Date of sale of 5,587 shares of common stock by Maximo F. Nougues. |
| 07/09/2025 | Date of sale of 3,935 shares of common stock by Maximo F. Nougues. |
| 07/10/2025 | Date of signature for the Form 4 filing. |
Keywords
Puma Biotechnology, PBYI, Maximo F. Nougues, Chief Financial Officer, Insider Trading, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.